Joslyn Campbell, MD
Nephrology · Houston, TXNPI 1912909847
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,745 of the $3,905 with a category attached, or 95.9%. Genentech USA, Inc. accounts for 95.9% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $2,398, more than ten times the $19 reported in 2019.
Across 11 payments — averaging $355.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$4K
- Medtronic$36
- Novartis$33
- Vifor Pharma, Inc.$29
- Veloxis Pharmaceuticals, Inc.$24
- Cormedix Inc.$20
- plus $19 from 1 others
Across 5 payments — averaging $1129.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$6K
What the payments were for
- Consulting fees$3,74596%
- Food & beverage$1604%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 3 | $3,745 |
| Medtronic | 2 | $36 |
| Novartis | 1 | $33 |
| Vifor Pharma, Inc. | 2 | $29 |
| Veloxis Pharmaceuticals, Inc. | 1 | $24 |
| Cormedix Inc. | 1 | $20 |
| Abbott | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,905 in reported general payments places this provider in the 70th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 17 | $37,534 |
| Sevelamer Carbonate | 62 | $14,996 |
| LokelmaSodium Zirconium Cyclosilicate | 15 | $8,590 |
| Gabapentin | 14 | $564 |
| Losartan Potassium | 26 | $474 |
| Doxazosin Mesylate | 16 | $373 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 12 | $178 |
| Spironolactone | 15 | $169 |
| Carvedilol | 31 | $167 |
| Prednisone | 34 | $167 |
| Oxybutynin Chloride ErOxybutynin Chloride | 12 | $81 |
| Temazepam | 13 | $76 |
| Furosemide | 13 | $60 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Houston
- Sreedhar MandayamHouston$752K
- Christopher KwohHouston$467K
- Wolfgang WinkelmayerHouston$462K
- Namrata GoelHouston$426K
- Dana MitchellHouston$344K
- Ramachandra MalyaHouston$312K
- John ForingerHouston$215K
- Biruh WorkenehHouston$185K
- Horacio AdrogueHouston$122K
- Anand SaranathanHouston$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.